BEAM THERAPEUTICS Trademark
Trademark Overview
On Wednesday, October 4, 2023, a trademark application was filed for BEAM THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the BEAM THERAPEUTICS trademark a serial number of 98209503. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Wednesday, May 14, 2025. This trademark is owned by Beam Therapeutics Inc.. The BEAM THERAPEUTICS trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical and biological preparations based on base editing, base modification, nucleobase editing, nucleobase modification, nucleic acid editing, gene editing, gene modification, gene modulation, gene reprogramming, gene therapy, genome editing, genome modification, cell therapy, cellular modification, tissue modification, and organ modification for use in human therapeutics for the treatment of Sickle Cell Disease, Beta Thalassemia, Alpha-1 Antitrypsin Deficiency, Glycogen Storage Disease Ia, Cancer, T-Cell Cancer, T-Cell Acute Lymphoblastic Leukemia, CD7 positive Acute Myeloid Leukemia, and Stargardt Disease
General Information
| Serial Number | 98209503 |
| Word Mark | BEAM THERAPEUTICS |
| Filing Date | Wednesday, October 4, 2023 |
| Status | 730 - FIRST EXTENSION - GRANTED |
| Status Date | Wednesday, May 14, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, October 8, 2024 |
Trademark Statements
| Goods and Services | Pharmaceutical and biological preparations based on base editing, base modification, nucleobase editing, nucleobase modification, nucleic acid editing, gene editing, gene modification, gene modulation, gene reprogramming, gene therapy, genome editing, genome modification, cell therapy, cellular modification, tissue modification, and organ modification for use in human therapeutics for the treatment of Sickle Cell Disease, Beta Thalassemia, Alpha-1 Antitrypsin Deficiency, Glycogen Storage Disease Ia, Cancer, T-Cell Cancer, T-Cell Acute Lymphoblastic Leukemia, CD7 positive Acute Myeloid Leukemia, and Stargardt Disease |
| NOT AVAILABLE | "THERAPEUTICS" |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, October 13, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Beam Therapeutics Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Cambridge, MA 02142 |
| Party Name | Beam Therapeutics Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Cambridge, MA 02142 |
Trademark Events
| Event Date | Event Description |
| Saturday, October 7, 2023 | NEW APPLICATION ENTERED |
| Friday, October 13, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, May 24, 2024 | ASSIGNED TO EXAMINER |
| Thursday, May 30, 2024 | COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY |
| Thursday, May 30, 2024 | NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED |
| Thursday, May 30, 2024 | EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED |
| Thursday, May 30, 2024 | EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED |
| Thursday, August 22, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, August 22, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, August 22, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, September 4, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, September 18, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, October 8, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, October 8, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, November 19, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Wednesday, May 14, 2025 | SOU TEAS EXTENSION RECEIVED |
| Wednesday, May 14, 2025 | SOU EXTENSION 1 FILED |
| Wednesday, May 14, 2025 | SOU EXTENSION 1 GRANTED |
| Thursday, May 15, 2025 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
